Susan Allman

Learn More
PURPOSE Age-Related Eye Disease Study 2 (AREDS2) is a randomized, placebo-controlled study designed to determine whether supplementation with 10 mg of lutein and 2 mg of zeaxanthin per day can slow the rate of progression of age-related macular degeneration (AMD). Although some biomarkers of response to carotenoid supplementation such as serum(More)
Twenty-seven patients (mean age 72 years) with symptoms of congestive cardiac failure who had been controlled by treatment with 1 to 2 tablets per day of a combination preparation of frusemide (40 mg) and amiloride (5 mg) for at least 12 weeks were studied. The study was designed to assess the efficacy and tolerability of continuing treatment with the(More)
Forty elderly patients, aged 68 to 89 years, with congestive cardiac failure, who were attending a hospital out-patients department, entered an open, parallel group, comparative study of two diuretic combinations, 40 mg frusemide plus 5 mg amiloride per tablet and 0.5 mg bumetanide plus 573 mg slow-release potassium chloride per tablet. Patients were(More)
Forty-seven patients entered this comparison of frusemide-amiloride and cyclopenthiazide-potassium chloride in the treatment of congestive cardiac failure in general practice. Frusemide-amiloride was 'very satisfactory' in 92% of the patients compared to only 55% who took cyclopenthiazide-potassium chloride. Significantly more patients were free of(More)
A total of 71 patients with cardiac failure requiring diuretic treatment were randomly allocated to receive either 20 mg frusemide/2.5 mg amiloride or 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium once daily for 12 weeks. Of the 35 patients treated with cyclopenthiazide/potassium, in 47% of patients the daily dose was doubled compared with(More)
Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment. After a 2-week run-in period when no antihypertensive medication was(More)
In an open, randomized, parallel group study lasting 8 weeks, nine males and nine females with mild congestive cardiac failure were initially treated daily with 20 mg frusemide/2.5 mg amiloride or 0.5 mg bumetanide/573 mg potassium chloride. In two patients receiving the frusemide combination and in one receiving the bumetanide combination, the daily dose(More)
  • 1